Human Microbiome Market – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning / Landscape Review & Global Market Size Forecast to 2034
Overview
Global Human Microbiome Market was valued US$ 930.99 Mn in 2025 and is expected to reach US$ 3458.96 Mn by 2034, at a CAGR of around 15.7 % during a forecast period.
Human Microbiome Research is advancing, and it is becoming obvious that a wide range of non-communicable diseases, including gastrointestinal inflammation, metabolic problems, and even cardiovascular, pulmonary, and neurological ailments, may be linked to imbalances in gut microbiota. Microbiomes have the potential to cure a variety of medical problems, including inflammatory bowel disease, obesity, diabetes, and others. However, new diagnostic techniques are required to serve this emerging industry.
Numerous companies are investing in emerging diagnostic methods. Major Players in the Human Microbiome market are identified through secondary research and their market revenues are determined through primary and secondary research. Some of the leading key players in the global Human Microbiome market include Metabiomics Corporation, Yakult Honsha Co., Ltd., And Microbiome Therapeutics, LLC. They are continuously strategizing on mergers and acquisitions, strategic alliances, joint ventures, and partnerships for the growth of their market shares.
Human Microbiome Market Analysis from 2025 to 2034
To know about the Research Methodology:-Request Free Sample Report
The human microbiome is the collection of all microbiota that resides on or within any human tissues and bio fluids, including the skin, mammary glands, placenta, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, biliary, and gastrointestinal tracts. It includes; bacteria, archaea, fungi, protists, and viruses. The correlation of most microbes with the human body varies from being commensal and mutualistic to neutral and harmful. Human microbiome-based therapies are existing in the form of foods, prebiotics, diagnostic devices, probiotics, medical foods, drugs, and supplements. Technological advancements in metagenomics and next-generation sequencing have made microbiome-based testing easier and inexpensive.
The rising incidence of lifestyle-related diseases, globally, is a strong driver of the human microbiome market, as therapeutics may provide an alternative route to tackle significant healthcare challenges, such as obesity, autoimmune disorders, and antibiotic resistance, genomic disorders, Gastrointestinal diseases, cancer, Crohn’s syndrome, and bowel syndrome.
However, the strict government guidelines are intended to hamper the Human Microbiome Market to an extent. Lack of awareness, technological expertise, and skilled professionals pose significant limitations, ultimately restricting the growth of the Human Microbiome Market.
According to the Application segment, the therapeutics segment held the largest share of the market. The therapeutic segment is also expected to grow at a balanced rate during the forecast period, owing to the increase in digestive problems, increase in the drug-related side effects.
Region-wise, North America is likely to dominate the Market in the forecast period, because of, Increase in the number of ongoing clinical trials and early adoption of recently developed technologies On the other hand, the Europe market is booming as a result of growing initiatives by central government in research and development along with establishments of startups.
The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Market dynamics, structure by identifying and analyzing the market segments and project the global market size.
Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in Global Market.
Human Microbiome Market Recent Industry Developments
| Date | Company | Development | Impact |
|---|---|---|---|
| 01 July 2026 | AOB Pharma, Inc. (AOBiome) | AOB Pharma partnered with CRO Biorasi to execute a Phase 2b clinical trial evaluating its topical microbiome platform B244 in patients with moderate-to-severe acne vulgaris. | The partnership accelerates clinical readout timelines, expanding the company's live biotherapeutic skin-health pipeline across 13 global study sites. |
| 08 July 2026 | Seres Therapeutics | Seres Therapeutics presented early clinical proof-of-concept data for SER-155 demonstrating efficacy in reducing immune checkpoint inhibitor-related enterocolitis. | The positive clinical results validate the therapeutic application of bacterial consortia in mitigating severe gastrointestinal side effects during cancer immunotherapy. |
| 06 August 2026 | Vedanta Biosciences, Inc. | Vedanta Biosciences secured $60 million in new financing to fund commercial readiness and final preparation ahead of pivotal Phase 3 data for VE303. | The capital infusion strengthens the company's balance sheet to advance the first defined bacterial consortium candidate for preventing recurrent C. difficile infections. |
| 03 November 2025 | MaaT Pharma | MaaT Pharma announced positive pivotal Phase 3 ARES trial results evaluating Xervyteg (MaaT013) in acute Graft-versus-Host Disease (aGvHD). | The trial achieved a landmark 54% 1-year overall survival rate, supporting regulatory submissions for microbiome-driven immunomodulators in oncology. |
| 17 April 2026 | BiomeBank | Blackmores Group entered a strategic agreement investing up to $15 million into Australian microbial biotech leader BiomeBank. | The corporate partnership accelerates global commercialization and manufacturing scale-up for donor-derived and second-generation microbial therapies. |
Human Microbiome Market Scope: Inquire before buying
| Human Microbiome Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | US $ 930.99 Mn. |
| Forecast Period 2026 to 2034 CAGR: | 15.7 % | Market Size in 2034: | US $ 3458.96 Mn. |
| Segments Covered: | by Product | Probiotics Prebiotics Medical Foods Supplements Others |
|
| by Application | Therapeutics Diagnostics |
||
| by Diseases | Obesity Diabetes Autoimmune Disorder Metabolic & Gastrointestinal Disorders Cancer Other Diseases |
||
Human Microbiome Market, by Region
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Human Microbiome Market, Key Players
1. Enterome Bioscience
2. E.I. Du Pont De Nemours and Company
3. Merck & Co., Inc.
4. Metabiomics Corporation
5. Yakult Honsha Co., Ltd.
6. Microbiome Therapeutics, LLC
7. Osel, Inc.
8. Second Genome, Inc.
9. Vithera Pharmaceuticals
10. Vedanta Biosciences, Inc.
11. Seres Therapeutics
12. Synthetic Biologics Inc.
13. Synlogic Inc.
14. 4D pharma
15. Evelo Biosciences
16. OptiBiotix Health
17. Ferring Pharmaceuticals
18. BiomX
19. Kaleido
20. YSOPIA Bioscience
21. FlightPath
22. Finch Therapeutics
23. Quantbiome
24. Viome, Inc.
25. DayTwo
Frequently Asked Questions:
1] What segments are covered in the Human Microbiome Market report?
Ans. The segments covered in the Human Microbiome Market report are based on Product, Applications, Diseases.
2] Which region is expected to hold the highest share in the Human Microbiome Market?
Ans. The North America region is expected to hold the highest share in the Human Microbiome Market.
3] What is the market size of the Human Microbiome Market by 2034?
Ans. The market size of the Human Microbiome Market by 2034 is US$ 3458.96 Mn.
4] What is the forecast period for the Human Microbiome Market?
Ans. The forecast period for the Human Microbiome Market is 2026-2034.
5] What was the market size of the Human Microbiome Market in 2025?
Ans. The market size of the Human Microbiome Market in 2025 was US$ 930.99 Mn.